Trial intelligence / Profile preview

Chidamide + venetoclax + azacitidine bridging microtransplantation in untreated unfit AML

ChiCTR2100052494Phase 2Recruiting

Sponsor
First Affiliated Hospital of Nanchang University
Start
Nov 2021
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of tucidinostat, venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Complete remission rate. Started Nov 2021; status: recruiting.

02

Drugs

tucidinostatvenetoclaxazacitidine
03

Conditions

acute myeloid leukemia (AML)

Beyond the preview

Go deeper on ChiCTR2100052494.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2100052494.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call